Introduction
============

Membranous nephropathy (MN) represents a distinct glomerular disease.[@b1-ijnrd-11-033] It has been considered as one of the most frequent types of nephrotic syndrome (NS) among adults worldwide, accounting for approximately 25%--40% of all the adults with NS.[@b2-ijnrd-11-033],[@b3-ijnrd-11-033] MN can be classified into primary MN, also known as idiopathic MN (iMN), and secondary MN (sMN) based on different pathogenesis, and the most common subtype is iMN, accounting for approximately 75% of MN cases.[@b4-ijnrd-11-033] sMN could be induced by various conditions, such as malignancies (breast, ovarian, lung, and stomach cancers, and lymphoproliferative disorders), infections (human immunodeficiency virus, malaria, hepatitis B and C viruses), some systemic autoimmune diseases (rheumatoid arthritis and lupus), and the consumption of drugs and toxins.[@b5-ijnrd-11-033],[@b6-ijnrd-11-033] MN is characterized by non-selective proteinuria, with the nephrotic range of more than 3.5 g/day.[@b7-ijnrd-11-033] Patients diagnosed with MN have a high risk of developing end-stage renal disease. Therefore, further understanding of the clinicopathological characteristics and disease progression is crucial for diagnosis and treatment of MN.

According to the statistics, the clinical manifestation of MN is variable among MN cases, as well as in the disease prognosis.[@b8-ijnrd-11-033] Data have revealed that MN is common in middle and old age groups with the peak age of 31--60 years.[@b9-ijnrd-11-033] The incidence of MN is different between men and women, and the ratio of male to female is approximately 2:1.[@b10-ijnrd-11-033] In previous studies, some typical clinical manifestations have been identified in patients with MN, such as NS, edema, hypertension, renal failure, and microscopic hematuria.[@b11-ijnrd-11-033] According to the guidelines of pathology, MN cases can be divided into four pathological stages (stages I, II, III, and IV).[@b12-ijnrd-11-033],[@b13-ijnrd-11-033] Renal dysfunction can usually be detected in patients who have had MN for 5--10 years and pathological stage III or IV.[@b14-ijnrd-11-033] Given the diverse clinicopathological characteristics of MN patients, a better understanding of these features is necessary for MN detection and treatment.

In the present study, we retrospectively analyzed the clinicopathological features of patients with MN.

Ethics statement
================

The research of investigating clinical and laboratory data of in-hospital patients for "Analysis of clinicopathological features for patients with membranous nephropathy" was a retrospective study and has been evaluated; it was confirmed that the protocols were conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Chinese PLA General Hospital. Signed informed consents were obtained from all the participants and their families. All of the clinicopathological features and personal information were made anonymous in the current study.

Methods
=======

Patients
--------

A total of 231 patients who were diagnosed with MN at Chinese PLA General Hospital from January 1, 2013 to March 15, 2016 were enrolled in this study. The diagnoses were based on the pathological evaluation of percutaneous renal biopsy under B ultrasound guidance. Primary MN was identified without secondary causes based on clinical evaluations, such as lupus, chronic infection, tumors, and drug exposure. Moreover, the primary MN individuals were negative for antinuclear antibodies, anti-neutrophil cytoplasmic antibodies, and hepatitis virus tests. If the collected patients presented the following clinical symptoms, they were confirmed as having NS: heavy proteinuria: ≥50 mg/kg/day (or ≥40 mg/m^2^/h), or a proteinuria/creatininuria ratio \>2 (mg/mg); serum ALB \<25 g/L; edema. The medical history, clinical and pathological data of the patients were routinely recorded at biopsy. The pathological stage of the patients was also evaluated by two independent pathologists. In addition, the clinical characteristics of the collected patients were also recorded, including age, gender, blood pressure, urine sugar, and body mass index (BMI). We collected the basic characteristics of the patients at biopsy from the medical records. Signed informed consents were obtained from all the participants or their families.

Data collection
---------------

All of the patients underwent percutaneous renal biopsy with the guidance of ultrasound, and the collected renal samples were embedded in paraffin. The pathological stage of the renal samples was evaluated by two independent pathologists following the methods detailed by Churg and Ehrenreich.[@b15-ijnrd-11-033] Nineteen clinical parameters were tested from the urine and serum specimens, including anti-phospholipase A2 receptor (anti-PLA2R) antibodies, ALT, AST, total protein (TP), ALB, total bilirubin (TB), direct bilirubin (DB), ALP, GGT, glucose (GLU), urea nitrogen (UN), creatinine (Cr), uric acid (Ua), total cholesterol (TC), triglyceride (TG), CK, LDH, high density lipoprotein cholesterol (HDL), low density lipoprotein cholesterol (LDL), and D2. Moreover, immunofluorescence assay was carried out to detect the serum IgA, IgG, IgM, IgE, C3, and C4. For these analyses, Hitachi 7500 electron microscope was adopted for the electron microscopy observations.

Statistical analysis
--------------------

All the data used were expressed as mean ± SD, and the statistical analyses were conducted with SPSS 18.0 software (SPSS Inc., Chicago, IL, USA). The comparison for continuous variables between two groups were carried out by Student's *t*-test, while chi-square test was used to analyze the categorical variables between two groups. *P*\<0.05 was considered as statistically significant.

Results
=======

General data and clinical manifestation of the MN patients
----------------------------------------------------------

A total of 231 MN patients including 219 with primary MN and 12 with sMN were included in our study. The sMN cases were all caused by viral hepatitis infection. There were 135 males and 96 females with the ratio of male to female being 1.47. The mean age of the patients was 47.43±14.32 years (age range of 16--79 years). As shown in [Figure 1](#f1-ijnrd-11-033){ref-type="fig"}, most of the patients were 41--59 years old, accounting for 45% of the patients. A total of 76 patients (33%) were ≤40 years, and 52 cases (22%) were ≥60 years. Among all these patients, 82 (35.5%) cases had hypertension and 28 (12.1%) had diabetes, while 163 (70.6%) patients suffered from NS. The average results of systolic and diastolic blood pressure were 132.39±22.18 and 81.85±12.21 mmHg, respectively ([Table 1](#t1-ijnrd-11-033){ref-type="table"}).

All the clinical parameters were summarized in [Table 1](#t1-ijnrd-11-033){ref-type="table"}. According to the analyses in renal tissues and blood samples, we found increased serum anti-PLA2R antibodies with a mean concentration of 95.45±165.37, and 173 (74.9%) MN cases were positive to anti-PLA2R antibodies test. Compared to the normal reference range, the BMI, TC, TG, LDL, D2, IgA, and IgE were increased, but the IgG was decreased in patients with MN. Other clinical features were distributed within the normal range in all the patients with MN.

Effects of age on clinicopathological features of patients with MN
------------------------------------------------------------------

All the patients were classified into two groups based on their age: ≤50 years group (n=125) and \>50 years group (n=106). The clinicopathological parameters were compared between the two groups. From the results detailed in [Table 2](#t2-ijnrd-11-033){ref-type="table"}, we found that hypertension, anti-PLA2R antibodies, AST, UN, CK, and IgA were significantly increased in \>50 years group, while BMI, TP, ALB, TB, and Ua were significantly decreased in the \>50 years group (all *P*\<0.05). However, no difference was observed for the other clinical parameters between the two age groups (all *P*\>0.05).

Clinicopathological characteristics according to gender
-------------------------------------------------------

To uncover the relationship between the gender of patients and their clinicopathological features, the patients were divided into male group and female group. From the analysis results listed in [Table 3](#t3-ijnrd-11-033){ref-type="table"}, we found that patients with more advanced pathological stage were male (*P*=0.038). Besides, the ALT, DB, GGT, UN, Cr, Ua, CK, and IgE in males were remarkably higher than that in females (*P*\<0.05 for all). Inversely, the results of anti-PLA2R antibodies and IgM were decreased in males compared with females (both *P*\<0.05).

Association of histological stage with clinicopathological characteristics of MN patients
-----------------------------------------------------------------------------------------

In this study, 221 (95.7%) MN patients were pathologically diagnosed with stages I--II, and ten (4.3%) cases were stage III. We also analyzed the clinical characteristics of MN patients according to their pathological stages. In [Table 4](#t4-ijnrd-11-033){ref-type="table"}, the results showed that the patients with more advanced pathological stages were more frequently male than female (*P*=0.038), moreover, the MN patients with advanced stages were more likely to have increased Cr (*P*=0.021) and IgE (*P*=0.003) levels compared with those with stages I--II. There was no significant correlation between pathological stage and other clinical parameters (all *P*\>0.05).

The comparison of clinicopathological characteristics of MN patients based on their anti-PLA2R antibodies test
--------------------------------------------------------------------------------------------------------------

Based on anti-PLA2R antibodies test, MN patients were divided into PLA2R positive group (173, 74.89%), or negative group (58, 25.11%). Compared to negative group, there were more male patients in positive group (*P*=0.034), moreover, they were more likely to present NS (*P*\<0.001). Besides, MN patients positive for anti-PLA2R antibodies showed significantly decreased TP (*P*\<0.001), ALB (*P*\<0.001), TB (*P*=0.005), DB (*P*=0.001), IgG (*P*\<0.001), and upregulated CH (*P*=0.003), CK (*P*=0.020), LDL (*P*=0.003), and D2 (*P*=0.032) ([Table 5](#t5-ijnrd-11-033){ref-type="table"}).

Discussion
==========

MN is a common disease of the urinary system, which is characterized by the accumulation of immune deposits on the outer surface of the glomerular basement membrane.[@b16-ijnrd-11-033] Most MN cases are iMN, representing a major cause of idiopathic NS among the adult population.[@b17-ijnrd-11-033] Despite various therapeutic strategies, the therapeutic effects are far from satisfactory.[@b18-ijnrd-11-033]--[@b20-ijnrd-11-033] Most of iMN cases will suffer from NS, posing a serious threat to human health.[@b21-ijnrd-11-033] And even worse, growing evidences have indicated that MN usually shows high rate of recurrence and long disease course, which may occur at any stage in life.[@b22-ijnrd-11-033] So far, the molecular mechanisms underlying the progression of MN remain unclear, and the clinicopathological characteristics are variable in MN cases, bringing a heavy burden for MN diagnosis and treatment.[@b23-ijnrd-11-033]

In the current study, we investigated and analyzed the clinicopathological characteristics of 231 patients who were pathologically diagnosed with MN. The ratio of male to female in the patients was 1.47 and the mean age was 47.43±14.32. Most patients were 41--59 years old, accounting for 45% of all the cases. Among them, 163 (70.6%) cases were positive for NS, which was in accordance with the data in the previous studies. In addition to these general data, the analysis of clinical parameters indicated that serum anti-PLA2R antibodies, BMI, CH, TG, LDL, D2, IgA, and IgE were increased in the MN patients compared to the normal reference values, but IgG was decreased in MN patients. In subsequent analysis, we analyzed the clinical characteristics of MN patients according to their age. We found significant differences for hypertension, BMI, anti-PLA2R antibodies, AST, TP, ALB, TB, UN, Ua, CK, and IgA between MN patients in the ≤50 years group and those in the \>50 years group. MN patients with advanced age were more likely to exhibit poor performance in blood examinations, revealing the aggressive disease progression. The study carried out by Chen et al reported that old age and high blood indices were significantly correlated with poor prognosis of patients with iMN.[@b24-ijnrd-11-033] Therefore, timely and effective treatment and medical care is particularly important for older MN patients.

Gender has also been proven to be associated with disease progression in patients with MN.[@b25-ijnrd-11-033] In our study, we investigated the clinical characteristics of MN patients based on their gender. The results showed that ALT, DB, GGT, UN, Cr, Ua, CK, and IgE were remarkably higher in males than in females. These results might reveal that male MN patients are more likely to undergo rapid disease progression than female patients. The results are consistent with previous studies. A related study performed among Japanese MN cases demonstrated that male MN cases were more likely to develop end-stage renal diseases, and have a poor prognosis.[@b25-ijnrd-11-033] Furthermore, it has been reported that with aging, men presented obviously greater decrements in renal functions than women, moreover, they were more likely to suffer from progressive renal diseases, such as MN, IgA nephropathy, and polycystic kidney disease. The mechanisms underlying the phenomenon might be related to the cell death induced by androgens.[@b26-ijnrd-11-033] Inversely, anti-PLA2R antibodies and IgM were decreased in males compared with females. The abnormal results might be attributed to the relatively small sample size, different geographic areas, as well as the detection methods. Thus, further studies will be required to confirm our results.

According to the pathological classification method, MN can be divided into stages I, II, III, and IV. The MN stage I cases have normal glomeruli, which can be observed by light microscopy.[@b27-ijnrd-11-033] However, for MN patients with stage II--IV, the capillary wall thicken and the deposits are gradually incorporated into the glomerular basement membrane.[@b28-ijnrd-11-033] Pathological stage classification is an effective way to estimate disease progression. In our study, we found that the pathological stage was significantly correlated with patients' gender, Cr, and IgE. Advanced pathological stage was more likely to be observed in males than in females. Moreover, MN patients with advanced stage usually had increased Cr and IgE compared with those with stages I--II. IgE is an important factor in allergic reactions. Studies have demonstrated that patients with renal diseases showed high serum levels of IgE, moreover, serum IgE level might be significantly correlated with disease activity and clinical outcomes of NS.[@b29-ijnrd-11-033],[@b30-ijnrd-11-033] However, the functional roles of IgE in the pathogenesis of renal disease remains poorly understood. Further investigations are urgently needed to address the issues.

Anti-PLA2R antibodies is an important factor in the occurrence of MN.[@b31-ijnrd-11-033] In general, anti-PLA2R antibodies is considered as a useful biomarker for early diagnosis and prognosis in patients with MN.[@b32-ijnrd-11-033] In this study, we compared the baseline characteristics of MN patients according to their anti-PLA2R antibodies test results. The results demonstrated that MN cases who were positive for anti-PLA2R antibodies had significantly decreased TP, ALB, TB, DB, IgG; and upregulated CH, CK, LDL, D2. Furthermore, they were more likely to present NS. The data revealed that patients in the anti-PLA2R antibodies positive group had rapid disease progression. The conclusion is in line with the previous studies.[@b33-ijnrd-11-033] The podocyte lesion plays a key role in the etiology of MN. PLA2R is located at the surface of podocytes, and its abnormal expression may reveal the abnormal formation of immune complexes in situ, thus leading to damage in podocytes.[@b34-ijnrd-11-033]

Conclusion
==========

In conclusion, the clinicopathological characteristics are diverse among MN patients. Male and elderly MN patients are more likely to undergo a rapid disease progression. Furthermore, the clinical characteristics are significantly correlated with pathological stages and anti-PLA2R antibodies level. Due to the relatively small sample size, the results obtained in our study should be verified by well-designed studies with large sample size.
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###### 

Summary of the clinicopathological features of MN patients

  Parameters                 Results                    Reference range
  -------------------------- -------------------------- -----------------
  Age (years)                47.43±14.32                --
  Gender (male : female)     135:96                     --
  Blood pressure (mmHg)      132.39±22.18/81.85±12.21   --
  NS                         163 (70.6%)                --
  BMI (Kg/m^2^)              **25.87±4.75**             18.5--24.9
  anti-PLA2R (RU/mL)         95.45±165.37               --
  PLA2R positive (n, %)      173 (74.9%)                --
  ALT (U/L)                  21.08±16.48                0--40
  AST (U/L)                  18.60±9.29                 0--40
  TP (g/L)                   49.44±10.02                55--80
  ALB (g/L)                  26.92±6.98                 35--50
  TB (µmol/L)                7.64±3.52                  0--21
  DB (µmol/L)                1.46±1.14                  0--8.6
  ALP (U/L)                  59.14±16.68                0--130
  GGT (U/L)                  34.94±48.22                0--50
  GLU (mmol/L)               4.95±1.24                  3.4--6.2
  UN (mmol/L)                5.22±2.42                  1.8--7.5
  Cr (µmol/L)                75.10±24.66                30--110
  Ua (µmol/L)                346.97±95.84               104--444
  TC (mmol/L)                **7.07±2.34**              3.1--5.7
  TG (mmol/L)                **2.58±1.90**              0.4--1.7
  CK (U/L)                   102.65±139.16              2--200
  LDH (U/L)                  193.60±57.98               40--250
  HDL (mmol/L)               1.44±0.52                  1--1.6
  LDL (mmol/L)               **4.85±2.03**              0--3.4
  D2 (µg/L)                  **1.26±2.28**              0.0--0.5
  IgA (mg/dL)                **215.41±84.18**           70--180
  IgG (mg/dL)                **625.48±282.06**          700--1600
  IgM (mg/dL)                116.30±78.30               40--230
  IgE (mg/dL)                **126.13±188.48**          0--100
  C3 (mg/dL)                 114.86±24.32               90--180
  C4 (mg/dL)                 28.19±9.83                 10--40
  Diabetes                   28 (12.1%)                 --
  Viral hepatitis            12 (5.2%)                  --
  Hepatitis B                10 (4.3%)                  --
  Hepatitis C                2 (0.9%)                   --
  Pathological stage (III)   10 (4.3%)                  --

**Notes:** --, no data. Data are presented as mean ± SD and n (%). Bold data is statistically significant.

**Abbreviations:** BMI, body mass index; TC, total cholesterol; Cr, creatinine; DB, direct bilirubin; GLU, glucose; HDL, high density lipoprotein cholesterol; LDL, low density lipoprotein cholesterol; MN, membranous nephropathy; NS, nephrotic syndrome; TB, total bilirubin; TG, triglyceride; TP, total protein; Ua, uric acid; UN, urea nitrogen.

###### 

Clinicopathological features of patients stratified according to age

  Parameters                     Age range       *P*-value       
  ------------------------------ --------------- --------------- -----------
  Gender (male : female)         78:47           57:49           0.185
  Hypertension (%)               24.0            49.1            **0.000**
  Diabetes (%)                   9.6             15.1            0.202
  Viral hepatitis (%)            5.6             4.7             0.763
  NS (%)                         65.6            76.4            0.072
  BMI (Kg/m^2^)                  26.05±5.29      25.67±4.01      **0.010**
  Pathological stage (III) (%)   6.4             1.9             0.093
  Anti-PLA2R (RU/mL)             66.22±104.33    128.80±211.13   **0.001**
  ALT (U/L)                      21.79±15.16     20.44±18.00     0.806
  AST (U/L)                      17.47±5.93      19.98±11.98     **0.019**
  TP (g/L)                       50.23±11.19     48.54±8.35      **0.003**
  ALB (g/L)                      27.68±7.78      26.05±5.80      **0.001**
  TB (µmol/L)                    7.67±3.79       7.62±3.17       **0.048**
  DB (µmol/L)                    1.40±0.93       1.54±1.35       0.401
  ALP (U/L)                      54.81±15.64     64.34±16.40     0.456
  GGT (U/L)                      36.11±43.24     35.24±56.26     0.884
  GLU (mmol/L)                   4.87±1.31       5.04±1.14       0.554
  UN (mmol/L)                    4.72±1.75       5.83±2.92       **0.004**
  Cr (µmol/L)                    72.64±20.32     78.02±28.69     0.074
  Ua (µmol/L)                    356.58±104.41   337.34±85.24    **0.015**
  TC (mmol/L)                    7.12±2.41       7.04±2.28       0.318
  TG (mmol/L)                    2.54±1.73       2.65±2.09       0.221
  CK (U/L)                       93.17±62.05     113.38±193.91   **0.047**
  LDH (U/L)                      190.93±62.96    198.00±52.83    0.228
  HDL (mmol/L)                   1.39±0.50       1.50±0.54       0.787
  LDL (mmol/L)                   4.93±2.05       4.77±2.01       0.566
  D2 (µg/L)                      1.11±2.23       1.44±2.34       0.437
  IgA (mg/dL)                    204.71±79.76    226.94±88.33    **0.015**
  IgG (mg/dL)                    616.03±303.52   632.76±257.16   0.297
  IgM (mg/dL)                    112.79±67.28    119.77±89.71    0.118
  IgE (mg/dL)                    126.67±197.85   124.48±177.05   0.702
  C3 (mg/dL)                     114.64±25.13    115.26±23.36    0.090
  C4 (mg/dL)                     27.89±9.34      28.49±10.39     0.340

**Note:** Data are presented as mean ± SD unless otherwise stated. Bold data is statistically significant, *P*\<0.05.

**Abbreviations:** BMI, body mass index; TC, total cholesterol; Cr, creatinine; DB, direct bilirubin; GLU, glucose; HDL, high density lipoprotein cholesterol; LDL, low density lipoprotein cholesterol; NS, nephrotic syndrome; TB, total bilirubin; TG, triglyceride; TP, total protein; Ua, uric acid; UN, urea nitrogen.

###### 

Clinicopathological features of patients stratified according to gender

  Parameters                     Male (n=135)    Female (n=96)   *P*-value
  ------------------------------ --------------- --------------- -----------
  Age (years)                    47.04±14.70     47.95±13.76     0.280
  Hypertension (%)               40.0            29.2            0.090
  Diabetes (%)                   11.9            12.5            0.882
  Viral hepatitis (%)            3.7             7.3             0.226
  NS (%)                         74.1            65.6            0.165
  BMI (Kg/m^2^)                  26.12±4.35      25.54±5.24      0.357
  Pathological stage (III) (%)   6.7             1.0             **0.038**
  Anti-PLA2R (RU/mL)             77.83±119.78    119.55±211.97   **0.002**
  ALT (U/L)                      24.21±19.60     16.89±9.24      **0.016**
  AST (U/L)                      19.48±10.88     17.42±6.23      0.148
  TP (g/L)                       47.99±10.14     51.51±9.48      0.863
  ALB (g/L)                      26.37±7.26      27.73±6.50      0.271
  TB (µmol/L)                    7.93±3.66       7.25±3.27       0.109
  DB (µmol/L)                    1.61±1.33       1.26±0.76       **0.021**
  ALP (U/L)                      58.85±15.72     59.61±17.96     0.614
  GGT (U/L)                      45.22±61.42     22.31±17.34     **0.000**
  GLU (mmol/L)                   5.00±1.19       4.87±1.30       0.662
  UN (mmol/L)                    5.83±2.72       4.38±1.60       **0.019**
  Cr (µmol/L)                    84.73±24.40     61.57±17.59     **0.014**
  Ua (µmol/L)                    386.04±93.44    293.91±71.80    **0.007**
  TC (mmol/L)                    7.20±2.46       6.93±2.19       0.064
  TG (mmol/L)                    2.71±2.03       2.43±1.71       0.290
  CK (U/L)                       121.93±171.80   75.12±62.21     **0.019**
  LDH (U/L)                      196.90±64.39    190.34±49.10    0.209
  HDL (mmol/L)                   1.33±0.51       1.59±0.49       0.408
  LDL (mmol/L)                   4.98±2.14       4.68±1.87       0.089
  D2 (µg/L)                      1.33±2.49       1.17±1.96       0.361
  IgA (mg/dL)                    210.36±83.73    221.20±85.23    0.466
  IgG (mg/dL)                    583.46±288.10   679.46±266.66   0.428
  IgM (mg/dL)                    98.75±64.54     139.88±88.99    **0.022**
  IgE (mg/dL)                    146.86±204.62   96.30±159.14    **0.021**
  C3 (mg/dL)                     114.82±22.91    115.08±26.19    0.294
  C4 (mg/dL)                     28.95±10.01     27.08±9.49      0.513

**Note:** Data are presented as mean ± SD unless otherwise stated. Bold data is statistically significant, *P*\<0.05.

**Abbreviations:** BMI, body mass index; TC, total cholesterol; Cr, creatinine; DB, direct bilirubin; GLU, glucose; HDL, high density lipoprotein cholesterol; LDL, low density lipoprotein cholesterol; NS, nephrotic syndrome; TB, total bilirubin; TG, triglyceride; TP, total protein; Ua, uric acid; UN, urea nitrogen.

###### 

Association of pathological stage with clinicopathological data of MN patients

  Parameters               Pathological stage   *P*-value       
  ------------------------ -------------------- --------------- -----------
  Age (years)              47.57±14.17          43.90±17.17     0.705
  Gender (male : female)   126:95               9:1             **0.038**
  Hypertension (%)         34.8                 50.0            0.327
  Diabetes (%)             12.7                 0               0.230
  Viral hepatitis (%)      5.4                  0               0.449
  NS (%)                   70.6                 70.0            0.968
  BMI (Kg/m^2^)            25.84±4.70           26.63±5.92      0.364
  anti-PLA2R (RU/mL)       96.66±165.96         59.83±148.42    0.668
  ALT (U/L)                21.05±16.66          23.80±12.89     0.909
  AST (U/L)                18.70±9.36           17.06±7.25      0.856
  TP (g/L)                 49.19±9.84           55.30±12.14     0.548
  ALB (g/L)                26.73±6.91           31.35±7.15      0.905
  TB (µmol/L)              7.63±3.54            7.95±3.12       0.902
  DB (µmol/L)              1.45±1.15            1.67±0.84       0.675
  ALP (U/L)                59.34±16.71          55.14±15.48     0.535
  GGT (U/L)                35.69±50.50          36.34±19.31     0.508
  GLU (mmol/L)             4.96±1.25            4.52±0.42       0.163
  UN (mmol/L)              5.16±2.35            6.58±3.54       0.214
  Cr (µmol/L)              74.50±23.86          88.65±36.66     **0.021**
  Ua (µmol/L)              345.68±96.45         393.51±86.54    0.197
  TC (mmol/L)              7.10±2.35            6.51±2.33       0.664
  TG (mmol/L)              2.59±1.93            2.55±1.10       0.502
  CK (U/L)                 103.35±141.29        80.06±56.64     0.572
  LDH (U/L)                194.00±58.62         198.38±58.63    0.526
  HDL (mmol/L)             1.45±0.51            1.25±0.72       0.717
  LDL (mmol/L)             4.87±2.04            4.44±1.77       0.483
  D2 (µg/L)                1.30±2.32            0.45±0.25       0.136
  IgA (mg/dL)              216.08±84.79         189.18±72.97    0.507
  IgG (mg/dL)              617.93±275.25        750.10±413.81   0.483
  IgM (mg/dL)              117.55±79.21         81.73±42.58     0.226
  IgE (mg/dL)              119.70±180.77        256.20±293.05   **0.003**
  C3 (mg/dL)               115.09±24.17         111.22±27.82    0.552
  C4 (mg/dL)               28.35±9.89           24.14±7.47      0.301

**Note:** Data are presented as mean ± SD unless otherwise stated. Bold data is statistically significant, *P*\<0.05.

**Abbreviations:** BMI, body mass index; TC, total cholesterol; Cr, creatinine; DB, direct bilirubin; GLU, glucose; HDL, high density lipoprotein cholesterol; LDL, low density lipoprotein cholesterol; MN, membranous nephropathy; NS, nephrotic syndrome; TB, total bilirubin; TG, triglyceride; TP, total protein; Ua, uric acid; UN, urea nitrogen.

###### 

Comparison of clinicopathological data of MN patients based on their anti-PLA2R test

  Parameters               Anti-PLA2R      *P*-value       
  ------------------------ --------------- --------------- ---------------------------------------------------
  Age (years)              47.37±14.35     47.55±14.24     0.933
  Gender (male : female)   108:65          27:31           **0.034**
  Hypertension (%)         67 (38.73)      15 (25.86)      0.076
  Diabetes (%)             18 (10.40)      10 (17.24)      0.167
  Viral hepatitis (%)      11 (6.3.6)      1 (1.72)        0.301[a](#tfn9-ijnrd-11-033){ref-type="table-fn"}
  NS (%)                   133 (76.88)     30 (51.72)      \<**0.001**
  BMI (Kg/m^2^)            25.93±4.89      25.71±4.30      0.759
  ALT (U/L)                20.36±16.17     23.60±17.35     0.196
  AST (U/L)                18.97±10.04     17.60±6.45      0.334
  TP (g/L)                 47.66±9.63      54.78±9.21      \<**0.001**
  ALB (g/L)                25.67±6.66      30.70±6.54      \<**0.001**
  TB (µmol/L)              7.27±3.10       8.75±4.36       **0.005**
  DB (µmol/L)              1.31±0.79       1.91±1.75       **0.001**
  ALP (U/L)                58.63±15.54     60.75±19.64     0.403
  GGT (U/L)                35.86±53.07     35.29±37.55     0.941
  GLU (mmol/L)             4.93±1.26       5.00±1.18       0.705
  UN (mmol/L)              5.30±2.33       5.02±2.68       0.450
  Cr (µmol/L)              75.58±22.72     73.70±59.71     0.615
  Ua (µmol/L)              352.72±91.73    332.92±108.54   0.176
  TC (mmol/L)              7.35±2.31       6.28±2.29       **0.003**
  TG (mmol/L)              2.70±2.03       2.26±1.40       0.125
  CK (U/L)                 115.05±157.59   65.60±38.08     **0.020**
  LDH (U/L)                195.33±51.50    190.79±75.82    0.614
  HDL (mmol/L)             1.42±0.50       1.51±0.58       0.277
  LDL (mmol/L)             5.08±2.03       4.17±1.89       **0.003**
  D2 (µg/L)                1.45±2.48       0.70±1.39       **0.032**
  IgA (mg/dL)              212.78±83.50    221.30±97.29    0.510
  IgG (mg/dL)              578.53±268.00   760.02±284.50   \<**0.001**
  IgM (mg/dL)              110.46±71.83    132.67±93.85    0.063
  IgE (mg/dL)              126.51±183.50   123.12±203.40   0.907
  C3 (mg/dL)               114.23±24.26    117.02±24.44    0.455
  C4 (mg/dL)               28.72±9.94      26.48±9.34      0.135

**Notes:**

Case number less than 5 -- corrected *P*-value was used. Data are presented as mean ± SD unless otherwise stated. Bold data is statistically significant, *P*\<0.05.

**Abbreviations:** BMI, body mass index; TC, total cholesterol; Cr, creatinine; DB, direct bilirubin; GLU, glucose; HDL, high density lipoprotein cholesterol; LDL, low density lipoprotein cholesterol; MN, membranous nephropathy; NS, nephrotic syndrome; TB, total bilirubin; TG, triglyceride; TP, total protein; Ua, uric acid; UN, urea nitrogen.

[^1]: These authors contributed equally to this work
